Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Invested Capital (2016 - 2025)

Historic Return on Invested Capital for Theravance Biopharma (TBPH) over the last 12 years, with Q3 2025 value amounting to 0.07%.

  • Theravance Biopharma's Return on Invested Capital rose 2200.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year increase of 2200.0%. This contributed to the annual value of 0.35% for FY2024, which is 1500.0% down from last year.
  • Latest data reveals that Theravance Biopharma reported Return on Invested Capital of 0.07% as of Q3 2025, which was up 2200.0% from 0.03% recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Return on Invested Capital registered a high of 0.93% during Q1 2021, and its lowest value of 2.0% during Q3 2022.
  • For the 5-year period, Theravance Biopharma's Return on Invested Capital averaged around 0.01%, with its median value being 0.2% (2022).
  • As far as peak fluctuations go, Theravance Biopharma's Return on Invested Capital plummeted by -28900bps in 2022, and later skyrocketed by 17300bps in 2023.
  • Quarter analysis of 5 years shows Theravance Biopharma's Return on Invested Capital stood at 0.81% in 2021, then tumbled by -124bps to 0.2% in 2022, then plummeted by -37bps to 0.27% in 2023, then crashed by -36bps to 0.37% in 2024, then skyrocketed by 82bps to 0.07% in 2025.
  • Its last three reported values are 0.07% in Q3 2025, 0.03% for Q2 2025, and 0.4% during Q1 2025.